Alexza Pharmaceuticals, Inc. (Alexza) is a pharmaceutical company focused on the research, development and commercialization of products for the acute treatment of central nervous system (CNS) conditions. Alexza�s product candidates are based on its technology, the Staccato system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for systemic drug delivery. The Company has one product candidate in active development, AZ-002 (Staccato alprazolam), which is being developed for the treatment of acute repetitive seizures, sometimes called cluster seizures or ARS. Its product candidates not in active development are AZ-007 (Staccato zaleplon), AZ-104 (Staccato loxapine, low-dose) AZ-003 (Staccato fentanyl) and AZ-003 (Staccato fentanyl). The Company has retained all rights to the Staccato system and to its product candidates other than ADASUVE and AZ-104 (Staccato loxapine, low-dose).